Depression symptoms, 3 months
Depression symptoms will be measured with the Patient Health Questionnaire 9 (PHQ-9). This will be quantified as change in PHQ-9 score from baseline (pre-intervention) to 3-months (post-intervention).
Depression symptoms, 6 months
Depression symptoms will be measured with the Patient Health Questionnaire 9 (PHQ-9). This will be quantified as change in PHQ-9 score from baseline (pre-intervention) to 6-months (post-intervention).
Depression symptoms, 9 months
Depression symptoms will be measured with the Patient Health Questionnaire 9 (PHQ-9). This will be quantified as change in PHQ-9 score from baseline (pre-intervention) to 9-months (post-intervention).
Depression symptoms, 12 months
Depression symptoms will be measured with the Patient Health Questionnaire 9 (PHQ-9). This will be quantified as change in PHQ-9 score from baseline (pre-intervention) to 12-months (post-intervention).
Functional impairment, 3 months
Functional impairment will be measured with the World Health Organization (WHO) Disability Assessment Schedule (WHODAS). This will be quantified as change in WHODAS score from baseline (pre-intervention) to 3-months (post-intervention).
Functional impairment, 6 months
Functional impairment will be measured with the World Health Organization (WHO) Disability Assessment Schedule (WHODAS). This will be quantified as change in WHODAS score from baseline (pre-intervention) to 6-months (post-intervention).
Functional impairment, 9 months
Functional impairment will be measured with the World Health Organization (WHO) Disability Assessment Schedule (WHODAS). This will be quantified as change in WHODAS score from baseline (pre-intervention) to 9-months (post-intervention).
Functional impairment, 12 months
Functional impairment will be measured with the World Health Organization (WHO) Disability Assessment Schedule (WHODAS). This will be quantified as change in WHODAS score from baseline (pre-intervention) to 12-months (post-intervention).
Overall health profile, 3 months
A health profile will be generated for each individual using the EuroQol (EQ-5D-5L). This will be quantified as change in EQ-5D-5L score from baseline (pre-intervention) to 3-months (post-intervention).
Overall health profile, 6 months
A health profile will be generated for each individual using the EuroQol (EQ-5D-5L). This will be quantified as change in EQ-5D-5L score from baseline (pre-intervention) to 6-months (post-intervention).
Overall health profile, 9 months
A health profile will be generated for each individual using the EuroQol (EQ-5D-5L). This will be quantified as change in EQ-5D-5L score from baseline (pre-intervention) to 9-months (post-intervention).
Overall health profile, 12 months
A health profile will be generated for each individual using the EuroQol (EQ-5D-5L). This will be quantified as change in EQ-5D-5L score from baseline (pre-intervention) to 12-months (post-intervention).
Depression prevalence, 3 months
Depression prevalence will be quantified as the change in proportion of individuals with moderate-to-severe depression (PHQ-9>9) at each clinic from baseline (pre-intervention) to 3-months (post-intervention).
Depression prevalence, 6 months
Depression prevalence will be quantified as the change in proportion of individuals with moderate-to-severe depression (PHQ-9>9) at each clinic from baseline (pre-intervention) to 6-months (post-intervention).
Depression prevalence, 9 months
Depression prevalence will be quantified as the change in proportion of individuals with moderate-to-severe depression (PHQ-9>9) at each clinic from baseline (pre-intervention) to 9-months (post-intervention).
Depression prevalence, 12 months
Depression prevalence will be quantified as the change in proportion of individuals with moderate-to-severe depression (PHQ-9>9) at each clinic from baseline (pre-intervention) to 12-months (post-intervention).
ART Adherence, 3 months
Among patients with HIV, ART adherence will be measured in terms of whether HIV+ enrollees have returned to an IC3 for antiretrovirals (ARVs) within the past three months. This will be quantified as change in adherence rates from baseline (pre-intervention) to 3-months (post-intervention)
ART Adherence, 6 months
Among patients with HIV, ART adherence will be measured in terms of whether HIV+ enrollees have returned to an IC3 for antiretrovirals (ARVs) within the past three months. This will be quantified as change in adherence rates from baseline (pre-intervention) to 6-months (post-intervention)
ART Adherence, 9 months
Among patients with HIV, ART adherence will be measured in terms of whether HIV+ enrollees have returned to an IC3 for antiretrovirals (ARVs) within the past three months. This will be quantified as change in adherence rates from baseline (pre-intervention) to 9-months (post-intervention)
ART Adherence, 12 months
Among patients with HIV, ART adherence will be measured in terms of whether HIV+ enrollees have returned to an IC3 for antiretrovirals (ARVs) within the past three months. This will be quantified as change in adherence rates from baseline (pre-intervention) to 12-months (post-intervention)
Viral suppression among HIV+ patients, 3 months
Viral load will be measured among patients with HIV (copies per milliliter). The investigators will examine change in the proportion of HIV+ patients who are virally-suppressed from baseline (pre-intervention) to 3-months (post-intervention)
Viral suppression among HIV+ patients, 6 months
Viral load will be measured among patients with HIV (copies per milliliter). The investigators will examine change in the proportion of HIV+ patients who are virally-suppressed from baseline (pre-intervention) to 6-months (post-intervention)
Viral suppression among HIV+ patients, 9 months
Viral load will be measured among patients with HIV (copies per milliliter). The investigators will examine change in the proportion of HIV+ patients who are virally-suppressed from baseline (pre-intervention) to 9-months (post-intervention)
Viral suppression among HIV+ patients, 12 months
Viral load will be measured among patients with HIV (copies per milliliter). The investigators will examine change in the proportion of HIV+ patients who are virally-suppressed from baseline (pre-intervention) to 12-months (post-intervention)
HIV disease staging among HIV+ patients, 3 months
Among HIV+, staging will be assessed according to WHO criteria. The investigators will examine change in the proportion of HIV+ patients with advanced disease staging from baseline (pre-intervention) to 3-months (post-intervention)
HIV disease staging among HIV+ patients, 6 months
Among HIV+, staging will be assessed according to WHO criteria. The investigators will examine change in the proportion of HIV+ patients with advanced disease staging from baseline (pre-intervention) to 6-months (post-intervention)
HIV disease staging among HIV+ patients, 9 months
Among HIV+, staging will be assessed according to WHO criteria. The investigators will examine change in the proportion of HIV+ patients with advanced disease staging from baseline (pre-intervention) to 9-months (post-intervention)
HIV disease staging among HIV+ patients, 12 months
Among HIV+, staging will be assessed according to WHO criteria. The investigators will examine change in the proportion of HIV+ patients with advanced disease staging from baseline (pre-intervention) to 12-months (post-intervention)
Systolic blood pressure among hypertensive patients, 3 months
Among patients with hypertension, systolic blood pressure (SBP) will be measured at routine clinic visits. The investigators will examine change in the proportion of hypertensive patients with SBP below 140 (over 90) from baseline (pre-intervention) to 3-months (post-intervention)
Systolic blood pressure among hypertensive patients, 6 months
Among patients with hypertension, systolic blood pressure (SBP) will be measured at routine clinic visits. The investigators will examine change in the proportion of hypertensive patients with SBP below 140 (over 90) from baseline (pre-intervention) to 6-months (post-intervention)
Systolic blood pressure among hypertensive patients, 9 months
Among patients with hypertension, systolic blood pressure (SBP) will be measured at routine clinic visits. The investigators will examine change in the proportion of hypertensive patients with SBP below 140 (over 90) from baseline (pre-intervention) to 9-months (post-intervention)
Systolic blood pressure among hypertensive patients, 12 months
Among patients with hypertension, systolic blood pressure (SBP) will be measured at routine clinic visits. The investigators will examine change in the proportion of hypertensive patients with SBP below 140 (over 90) from baseline (pre-intervention) to 12-months (post-intervention)
A1C levels among diabetic patients, 3 months
Among patients with diabetes, A1C (or random blood sugar) levels will be assessed at routine clinic visits. The investigators will examine change in the proportion of diabetic patients with controlled A1C / blood sugar levels from baseline (pre-intervention) to 3-months (post-intervention)
A1C levels among diabetic patients, 6 months
Among patients with diabetes, A1C (or random blood sugar) levels will be assessed at routine clinic visits. The investigators will examine change in the proportion of diabetic patients with controlled A1C / blood sugar levels from baseline (pre-intervention) to 6-months (post-intervention)
A1C levels among diabetic patients, 9 months
Among patients with diabetes, A1C (or random blood sugar) levels will be assessed at routine clinic visits. The investigators will examine change in the proportion of diabetic patients with controlled A1C / blood sugar levels from baseline (pre-intervention) to 9-months (post-intervention)
A1C levels among diabetic patients, 12 months
Among patients with diabetes, A1C (or random blood sugar) levels will be assessed at routine clinic visits. The investigators will examine change in the proportion of diabetic patients with controlled A1C / blood sugar levels from baseline (pre-intervention) to 12-months (post-intervention)
Number of seizures among patients with epilepsy, 3 months
Among patients with epilepsy, number of seizures will be documented during routine clinic visits. The investigator will examine change in the rate of seizures among epilepsy patients from baseline (pre-intervention) to 3-months (post-intervention)
Number of seizures among patients with epilepsy, 6 months
Among patients with epilepsy, number of seizures will be documented during routine clinic visits. The investigator will examine change in the rate of seizures among epilepsy patients from baseline (pre-intervention) to 6-months (post-intervention)
Number of seizures among patients with epilepsy, 9 months
Among patients with epilepsy, number of seizures will be documented during routine clinic visits. The investigator will examine change in the rate of seizures among epilepsy patients from baseline (pre-intervention) to 9-months (post-intervention)
Number of seizures among patients with epilepsy, 12 months
Among patients with epilepsy, number of seizures will be documented during routine clinic visits. The investigator will examine change in the rate of seizures among epilepsy patients from baseline (pre-intervention) to 12-months (post-intervention)